AR124084A1 - ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO - Google Patents
ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATOInfo
- Publication number
- AR124084A1 AR124084A1 ARP210103178A ARP210103178A AR124084A1 AR 124084 A1 AR124084 A1 AR 124084A1 AR P210103178 A ARP210103178 A AR P210103178A AR P210103178 A ARP210103178 A AR P210103178A AR 124084 A1 AR124084 A1 AR 124084A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- folr1
- antibodies
- heavy chain
- folate receptor
- Prior art date
Links
- 229940014144 folate Drugs 0.000 title 1
- 239000011724 folic acid Substances 0.000 title 1
- 102000010451 Folate receptor alpha Human genes 0.000 abstract 6
- 108050001931 Folate receptor alpha Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 1
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 1
- 230000003432 anti-folate effect Effects 0.000 abstract 1
- 229940127074 antifolate Drugs 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000004052 folic acid antagonist Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen anticuerpos de cadena pesada del receptor a anti-folato (FOLR1) (por ejemplo, UniAbsTM), junto con métodos para elaborar tales anticuerpos, composiciones, incluidas las composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos que se caracterizan por la expresión del receptor a de folato (FOLR1). Reivindicación 1: Un anticuerpo que se une a FOLR1, el que comprende una primera región variable de cadena pesada que comprende: (a) una secuencia de CDR1 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoácidos de las SEQ ID Nº 1 - 5; y/o (b) una secuencia de CDR2 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoácidos de las SEQ ID Nº 6 - 17; y/o (c) una secuencia de CDR3 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoácidos de las SEQ ID Nº 18 - 22. Reivindicación 46: Una composición farmacéutica que comprende el anticuerpo de una cualquiera de las reivindicaciones 1 a 45. Reivindicación 51: Un polinucleótido que codifica un anticuerpo de cualquiera de las reivindicaciones 1 a 45. Reivindicación 52: Un vector que comprende el polinucleótido de la reivindicación 51. Reivindicación 53: Una célula que comprende el vector de la reivindicación 52. Reivindicación 54: Un método para producir un anticuerpo de cualquiera de las reivindicaciones 1 a 45, el que comprende cultivar una célula de acuerdo con la reivindicación 53 en condiciones permisivas para la expresión del anticuerpo y aislar el anticuerpo de la célula. Reivindicación 55: Un método para elaborar un anticuerpo de cualquiera de las reivindicaciones 1 a 45, el que comprende inmunizar un animal UniRat con una proteína FOLR1 e identificar las secuencias de los anticuerpos que se unen a FOLR1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115436P | 2020-11-18 | 2020-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124084A1 true AR124084A1 (es) | 2023-02-08 |
Family
ID=79024440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103178A AR124084A1 (es) | 2020-11-18 | 2021-11-17 | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240002498A1 (es) |
| EP (1) | EP4247498A1 (es) |
| JP (1) | JP2023549851A (es) |
| KR (1) | KR20230110303A (es) |
| CN (1) | CN116615253A (es) |
| AR (1) | AR124084A1 (es) |
| AU (1) | AU2021383743A1 (es) |
| CA (1) | CA3199785A1 (es) |
| CL (1) | CL2023001432A1 (es) |
| CO (1) | CO2023006790A2 (es) |
| CR (1) | CR20230259A (es) |
| IL (1) | IL302670A (es) |
| MX (1) | MX2023005693A (es) |
| PE (1) | PE20231203A1 (es) |
| TW (1) | TW202233684A (es) |
| UY (1) | UY39522A (es) |
| WO (1) | WO2022109010A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017316604C1 (en) | 2016-08-24 | 2025-01-30 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| BR112019012354A2 (pt) | 2016-12-21 | 2019-11-26 | Teneobio Inc | anticorpos apenas de cadeia pesada anti-bcma |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| EA202192736A1 (ru) | 2019-04-05 | 2022-01-27 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с псма |
| BR112021024956A2 (pt) | 2019-06-14 | 2022-01-25 | Teneobio Inc | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| MXPA05004677A (es) | 2002-10-31 | 2005-11-17 | Genentech Inc | Metodos y composiciones para aumentar la produccion de anticuerpos. |
| US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| EP2311874B1 (en) | 2004-07-22 | 2017-05-31 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| DK2406284T5 (en) | 2009-03-10 | 2017-06-12 | Biogen Ma Inc | ANTI-BCMA ANTIBODIES |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) * | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| PL4141032T3 (pl) * | 2014-11-20 | 2024-09-16 | F. Hoffmann-La Roche Ag | Terapia skojarzona składająca się z dwuswoistych cząsteczek wiążących antygen aktywujących limfocyty T oraz antagonistów wiązania osi PD-1 |
| WO2016079076A1 (en) * | 2014-11-20 | 2016-05-26 | F. Hoffmann-La Roche Ag | T cell activating bispecific antigen binding molecules agiant folr1 and cd3 |
| JP7432363B2 (ja) | 2016-06-21 | 2024-02-16 | テネオバイオ， インコーポレイテッド | Ｃｄ３結合抗体 |
| AU2017316604C1 (en) | 2016-08-24 | 2025-01-30 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| CR20220408A (es) | 2016-09-14 | 2022-10-20 | Teneobio Inc | ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198) |
| CA3091683A1 (en) * | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
| EA202192736A1 (ru) * | 2019-04-05 | 2022-01-27 | Тенеобио, Инк. | Антитела, содержащие только тяжелые цепи, которые связываются с псма |
-
2021
- 2021-11-11 TW TW110142033A patent/TW202233684A/zh unknown
- 2021-11-17 KR KR1020237020120A patent/KR20230110303A/ko active Pending
- 2021-11-17 PE PE2023001680A patent/PE20231203A1/es unknown
- 2021-11-17 IL IL302670A patent/IL302670A/en unknown
- 2021-11-17 CN CN202180077625.6A patent/CN116615253A/zh active Pending
- 2021-11-17 EP EP21824720.3A patent/EP4247498A1/en active Pending
- 2021-11-17 AU AU2021383743A patent/AU2021383743A1/en active Pending
- 2021-11-17 CA CA3199785A patent/CA3199785A1/en active Pending
- 2021-11-17 WO PCT/US2021/059701 patent/WO2022109010A1/en not_active Ceased
- 2021-11-17 CR CR20230259A patent/CR20230259A/es unknown
- 2021-11-17 MX MX2023005693A patent/MX2023005693A/es unknown
- 2021-11-17 JP JP2023528641A patent/JP2023549851A/ja active Pending
- 2021-11-17 US US18/253,197 patent/US20240002498A1/en active Pending
- 2021-11-17 AR ARP210103178A patent/AR124084A1/es unknown
- 2021-11-18 UY UY0001039522A patent/UY39522A/es unknown
-
2023
- 2023-05-18 CL CL2023001432A patent/CL2023001432A1/es unknown
- 2023-05-25 CO CONC2023/0006790A patent/CO2023006790A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116615253A (zh) | 2023-08-18 |
| CL2023001432A1 (es) | 2024-01-05 |
| IL302670A (en) | 2023-07-01 |
| UY39522A (es) | 2022-06-30 |
| EP4247498A1 (en) | 2023-09-27 |
| PE20231203A1 (es) | 2023-08-17 |
| CO2023006790A2 (es) | 2023-06-09 |
| AU2021383743A1 (en) | 2023-06-08 |
| TW202233684A (zh) | 2022-09-01 |
| CR20230259A (es) | 2023-07-13 |
| CA3199785A1 (en) | 2022-05-27 |
| US20240002498A1 (en) | 2024-01-04 |
| WO2022109010A1 (en) | 2022-05-27 |
| KR20230110303A (ko) | 2023-07-21 |
| AU2021383743A9 (en) | 2024-09-26 |
| MX2023005693A (es) | 2023-05-29 |
| JP2023549851A (ja) | 2023-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
| PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20181956A1 (es) | Polipeptidos que inhiben cd40l | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
| AR123628A1 (es) | Constructos anti-cd93 y usos de estos | |
| AR101202A1 (es) | Anticuerpo anti-tie2 humana | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| PE20240761A1 (es) | Proteinas de union a psma y usos de estas | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| EA202192907A1 (ru) | Моноклональное антитело, которое специфически связывается с gitr | |
| RU2016141285A (ru) | Биспецифические антигенсвязывающие полипептиды | |
| MX2022003074A (es) | Anticuerpos anti-cd371, y usos de los mismos. |